Ignite Creation Date:
2024-05-06 @ 12:21 PM
Last Modification Date:
2024-10-26 @ 12:57 PM
Study NCT ID:
NCT03730038
Status:
COMPLETED
Last Update Posted:
2020-10-19
First Post:
2018-11-01
Brief Title:
Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia
Sponsor:
Yonsei University
Organization:
Yonsei University
Study Overview
Official Title:
Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia A Randomized Crossover Trial
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Leucine-rich glioma inactivated 3Lgi3 has been postulated to have a pro-inflammatory adipokine that inter-plays with other adipokines in adipogenesis and metabolic inflammation according to recent investigations Thus in this study we sought to demonstrate that the treatment of statin can decrease Lgi3 level along with the decrease of the atherosclerosis to further evaluate the role of Lgi3 in atherosclerosis
Detailed Description:
Patients who assigned to the pitavastatin treatment first group will be given the pitavastatin 4 mg qd treatment for 12 weeks after randomization followed by wash-out period of 3 weeks and life-style modification treatment for 12 weeks Similarly patients who assigned to the life-style modification treatment first group will be treated with life-style modification treatment for 12 weeks after randomization followed by wash-out period of 3 weeks and pitavastatin treatment for 12 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None